{"organizations": [], "uuid": "3781adccde6e577db8d7ad162d96fc8b442a4937", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.pharmamedtechbi.com", "main_image": "", "site_section": "http://feeds.feedburner.com/PharmaBiotechFinancing", "section_title": "Pharma/Biotech Financing From Elsevier Business Intelligence", "url": "https://www.pharmamedtechbi.com/deals/201530756?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "country": "IL", "title": "Galera closes $37mm Series B round", "performance_score": 0, "site": "pharmamedtechbi.com", "participants_count": 0, "title_full": "Galera closes $37mm Series B round", "spam_score": 0.0, "site_type": "news", "published": "2015-10-17T02:40:00.000+03:00", "replies_count": 0, "uuid": "3781adccde6e577db8d7ad162d96fc8b442a4937"}, "author": "", "url": "https://www.pharmamedtechbi.com/deals/201530756?elsca1=custom&elsca2=rss&elsca3=%3ftype%3dDeals%26advanced%3d(%2540industries%253d%2522Pharmaceuticals%2522)%2520and%2520(%2540industries%253d%2522Biotechnology%2522)%2520and%2520(%2540dealtype%253d%2522Financing%2522)", "ord_in_thread": 0, "title": "Galera closes $37mm Series B round", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Galera closes $37mm Series B round Deal Date: Oct-01-2015 / Deal # 201530756 Executive Summary \nGalera Therapeutics Inc. raised $37mm through its Series B round that was led by Novo Ventures (which also joins the company's board). Returning backers New Enterprise Associates, Novartis Venture Fund, Correlation Ventures, and Galera Angels also took part. Proceeds will fund continued advancement (and potential indication expansion) of Galera's pipeline of dismutase mimetics, including lead Phase II candidate GC4419 for oral mucositis in patients with head and neck cancer.", "external_links": [], "published": "2015-10-17T02:40:00.000+03:00", "crawled": "2015-10-17T19:14:27.811+03:00", "highlightTitle": ""}